Willow Biosciences Inc (WLLW) - Net Assets
Based on the latest financial reports, Willow Biosciences Inc (WLLW) has net assets worth CA$-690.00K CAD (≈ $-499.14K USD) as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$2.31 Million ≈ $1.67 Million USD) and total liabilities (CA$3.00 Million ≈ $2.17 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Willow Biosciences Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$-690.00K |
| % of Total Assets | -29.83% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -150.17% |
| Growth Volatility | 665.21 |
Willow Biosciences Inc - Net Assets Trend (2000–2024)
This chart illustrates how Willow Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Also explore Willow Biosciences Inc assets under control for the complete picture of this company's asset base.
Annual Net Assets for Willow Biosciences Inc (2000–2024)
The table below shows the annual net assets of Willow Biosciences Inc from 2000 to 2024. For live valuation and market cap data, see WLLW stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CA$-505.00K ≈ $-365.31K |
-114.70% |
| 2023-12-31 | CA$3.44 Million ≈ $2.49 Million |
-79.02% |
| 2022-12-31 | CA$16.37 Million ≈ $11.84 Million |
-44.84% |
| 2021-12-31 | CA$29.68 Million ≈ $21.47 Million |
+5409.84% |
| 2020-12-31 | CA$-559.00K ≈ $-404.37K |
-102.54% |
| 2019-12-31 | CA$22.01 Million ≈ $15.92 Million |
+2535.68% |
| 2018-12-31 | CA$835.03K ≈ $604.05K |
+675.86% |
| 2017-12-31 | CA$-145.01K ≈ $-104.90K |
+62.17% |
| 2016-12-31 | CA$-383.33K ≈ $-277.30K |
-138.08% |
| 2015-12-31 | CA$1.01 Million ≈ $728.19K |
-27.17% |
| 2014-12-31 | CA$1.38 Million ≈ $999.85K |
-3.76% |
| 2013-12-31 | CA$1.44 Million ≈ $1.04 Million |
+59.31% |
| 2012-12-31 | CA$901.49K ≈ $652.12K |
-64.33% |
| 2011-12-31 | CA$2.53 Million ≈ $1.83 Million |
-28.27% |
| 2010-12-31 | CA$3.52 Million ≈ $2.55 Million |
-32.78% |
| 2009-12-31 | CA$5.24 Million ≈ $3.79 Million |
+50.82% |
| 2008-12-31 | CA$3.47 Million ≈ $2.51 Million |
+39.09% |
| 2007-12-31 | CA$2.50 Million ≈ $1.81 Million |
+11463.82% |
| 2006-12-31 | CA$-21.98K ≈ $-15.90K |
+79.91% |
| 2005-12-31 | CA$-109.44K ≈ $-79.17K |
+84.69% |
| 2004-12-31 | CA$-714.97K ≈ $-517.20K |
-5.99% |
| 2002-12-31 | CA$-674.55K ≈ $-487.96K |
-11.62% |
| 2001-12-31 | CA$-604.35K ≈ $-437.18K |
-37.03% |
| 2000-12-31 | CA$-441.04K ≈ $-319.04K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Willow Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12549010700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$127.37 Million | % |
| Total Equity | CA$-505.00K | 100.00% |
Willow Biosciences Inc Competitors by Market Cap
The table below lists competitors of Willow Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
YGL Convergence Bhd
KLSE:0086
|
$5.15 Million |
|
Oberstdorfer Bergbahn AG
MU:KVO
|
$5.16 Million |
|
abrdn Asian Income Fund Limited
LSE:AAIF
|
$5.17 Million |
|
Vintage Energy Ltd
AU:VEN
|
$5.17 Million |
|
Mask Investments Limited
NSE:MASKINVEST
|
$5.14 Million |
|
Mainz Biomed N.V.
NASDAQ:QUCY
|
$5.14 Million |
|
Rayong Wire Industries Public Company Limited
BK:RWI
|
$5.14 Million |
|
Better Choice Company Inc
NYSE MKT:BTTR
|
$5.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Willow Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,436,000 to -505,000, a change of -3,941,000 (-114.7%).
- Net loss of 6,189,000 reduced equity.
- New share issuances of 1,910,000 increased equity.
- Other comprehensive income increased equity by 369,000.
- Other factors decreased equity by 31,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-6.19 Million | -1225.54% |
| Share Issuances | CA$1.91 Million | +378.22% |
| Other Comprehensive Income | CA$369.00K | +73.07% |
| Other Changes | CA$-31.00K | -6.14% |
| Total Change | CA$- | -114.70% |
Book Value vs Market Value Analysis
This analysis compares Willow Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | CA$-12.42 | CA$0.17 | x |
| 1999-12-31 | CA$-218.55 | CA$0.17 | x |
| 2000-12-31 | CA$-375.67 | CA$0.17 | x |
| 2001-12-31 | CA$-514.78 | CA$0.17 | x |
| 2002-12-31 | CA$-574.58 | CA$0.17 | x |
| 2003-12-31 | CA$-961.45 | CA$0.17 | x |
| 2004-12-31 | CA$-413.76 | CA$0.17 | x |
| 2005-12-31 | CA$-44.40 | CA$0.17 | x |
| 2006-12-31 | CA$-6.41 | CA$0.17 | x |
| 2007-12-31 | CA$525.36 | CA$0.17 | x |
| 2008-12-31 | CA$536.55 | CA$0.17 | x |
| 2009-12-31 | CA$532.45 | CA$0.17 | x |
| 2010-12-31 | CA$292.98 | CA$0.17 | x |
| 2011-12-31 | CA$190.32 | CA$0.17 | x |
| 2012-12-31 | CA$64.56 | CA$0.17 | x |
| 2013-12-31 | CA$32.25 | CA$0.17 | x |
| 2014-12-31 | CA$16.81 | CA$0.17 | x |
| 2015-12-31 | CA$7.47 | CA$0.17 | x |
| 2016-12-31 | CA$-1.38 | CA$0.17 | x |
| 2017-12-31 | CA$-0.20 | CA$0.17 | x |
| 2018-12-31 | CA$0.38 | CA$0.17 | x |
| 2019-12-31 | CA$0.31 | CA$0.17 | x |
| 2020-12-31 | CA$-0.01 | CA$0.17 | x |
| 2021-12-31 | CA$0.25 | CA$0.17 | x |
| 2022-12-31 | CA$0.13 | CA$0.17 | x |
| 2023-12-31 | CA$0.03 | CA$0.17 | x |
| 2024-12-31 | CA$0.00 | CA$0.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Willow Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -132.75%
- • Asset Turnover: 1.87x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-62.37%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-187.78K |
| 1999 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-88.65K |
| 2000 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-139.05K |
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-102.87K |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-2.75K |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-208.06K |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-146.30K |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-379.41K |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-402.21K |
| 2007 | -66.14% | 0.00% | 0.00x | 1.23x | CA$-1.90 Million |
| 2008 | -33.16% | 0.00% | 0.00x | 1.26x | CA$-1.50 Million |
| 2009 | -58.34% | 0.00% | 0.00x | 1.06x | CA$-3.58 Million |
| 2010 | -91.32% | 0.00% | 0.00x | 1.06x | CA$-3.57 Million |
| 2011 | -56.08% | 0.00% | 0.00x | 1.20x | CA$-1.67 Million |
| 2012 | -199.73% | 0.00% | 0.00x | 2.37x | CA$-1.89 Million |
| 2013 | -96.59% | 0.00% | 0.00x | 1.66x | CA$-1.53 Million |
| 2014 | -62.61% | 0.00% | 0.00x | 1.76x | CA$-1.00 Million |
| 2015 | -130.19% | 0.00% | 0.00x | 2.40x | CA$-1.41 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-2.29 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-1.84 Million |
| 2018 | -196.95% | -9723.67% | 0.02x | 1.16x | CA$-1.73 Million |
| 2019 | -202.49% | -972220.55% | 0.00x | 1.54x | CA$-46.77 Million |
| 2020 | 0.00% | -339860.00% | 0.00x | 0.00x | CA$-33.93 Million |
| 2021 | -20.78% | -4636.84% | 0.00x | 1.18x | CA$-9.14 Million |
| 2022 | -90.47% | -1804.38% | 0.05x | 1.11x | CA$-16.45 Million |
| 2023 | -379.19% | -1111.69% | 0.18x | 1.94x | CA$-13.37 Million |
| 2024 | 0.00% | -132.75% | 1.87x | 0.00x | CA$-6.14 Million |
Industry Comparison
This section compares Willow Biosciences Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $215,484,723
- Average return on equity (ROE) among peers: -94.21%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Willow Biosciences Inc (WLLW) | CA$-690.00K | 0.00% | N/A | $5.15 Million |
| Aurora Cannabis Inc (ACB) | $694.20K | -56.68% | 0.04x | $193.63 Million |
| Amotiv Limited (AOV) | $746.87 Million | -2.25% | 0.27x | $553.67 Million |
| Aequus Pharmaceuticals Inc (AQS) | $2.92 Million | -82.54% | 0.25x | $479.73K |
| Avicanna Inc (AVCN) | $3.46 Million | -426.03% | 4.09x | $13.17 Million |
| Avant Brands Inc (AVNT) | $84.59K | -18.22% | 0.47x | $4.13 Million |
| Bausch Health Companies Inc (BHC) | $1.28 Billion | 15.87% | 0.69x | $2.06 Billion |
| CanadaBis Capital Inc (CANB) | $317.23K | -43.61% | 0.10x | $1.53 Million |
| Cannabist Company Holdings Inc (CBST) | $65.35 Million | -268.87% | 11.60x | $12.59 Million |
| Cipher Pharmaceuticals Inc (CPH) | $28.01 Million | 11.57% | 0.66x | $326.62 Million |
| Cardiol Therapeutics Inc Class A (CRDL) | $22.27 Million | -71.36% | 0.11x | $148.65 Million |
About Willow Biosciences Inc
Willow Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has licensing and development partnership with Laurus Labs to develop and commercialize active pharmaceutical ingredients and other ingredients. Willow Biosciences Inc. was founded in 20… Read more